Ibogaine, a naturally occurring alkaloid found in  Tabernanthe iboga  and
other plant species of Central West Africa, was first reported to be
effective in interrupting opiate narcotic dependence disorders in U.S.
patent 4,499,096 (Lotsof, 1985); cocaine dependence disorders in U.S.
patent  4.587,243 (Lotsof, 1986) and poly-drug dependence disorders in
U.S. patent 5,152,994 (Lotsof, 1992). The initial studies demonstrating
Ibogaine's effects on cocaine and heroin dependence were accomplished in a
series of focus group experiments by H. S. Lotsof in 1962 and 1963.
Additional data on the clinical aspects of Ibogaine in the treatment of
chemical dependence were reported by Kaplan (1993),  Sisko (1993),
Sanchez-Ramos & Mash (1994),  Sheppard (1994), Judd (1994) and Mash et al.
Prior to Ibogaine's evaluation for the interruption of various chemical
dependencies, the use of Ibogaine was reported in psychotherapy by Naranjo
(1969, 1973)  and at the First International Ibogaine Conference held in
Paris (Zeff, 1987).  The use of Ibogaine-containing plants has been
reported for centuries in West Africa in both religious practice and in
traditional medicine (Fernandez, 1982; Gollnhofer & Sillans 1983, 1985)
Overviews of the history of Ibogaine research and use  were published by
Goutarel et al. (1993) and Popik et al. (1995)
Claims of efficacy  in treating dependencies to opiates, cocaine, and
alcohol in human subjects were supported in preclinical studies by
researchers  in the United States, the Netherlands and Canada.  Dzoljic et
al. (1988) were the first researchers to publish Ibogaine's ability to
attenuate narcotic withdrawal.   Stanley D. Glick et al. (1992) at Albany
Medical College published original research and a review of the field
concerning the attenuation of narcotic withdrawal. Maisonneuve et al.
(1991) determined the pharmacological interactions between Ibogaine and
morphine, and Glick et al. (1992)  reported  Ibogaine's ability to  reduce
or interrupt morphine self-administration in the rat.  Woods et al. (1990)
found that Ibogaine did not act as an opiate, and Aceto et al. (1991)
established that Ibogaine did not precipitate  withdrawal signs or cause
Cappendijk and Dzoljic (1993)  published Ibogaine's effect in reducing
cocaine self-administration in the rat.  Broderick et al. (1992)  first
published  Ibogaine's ability to reverse cocaine-induced dopamine
increases and later, on Ibogaine's reduction of cocaine-induced motor
activity and other effects (1994).  Broderick et al.'s research supported
the findings of Sershen et al. (1992),  that Ibogaine reduced
cocaine-induced motor stimulation in the mouse.  Sershen (1993) also
demonstrated that Ibogaine reduced the consumption of cocaine in mice.
Glick (1992) and Cappendijk (1993) discovered in the animal model  that
multiple administrations of Ibogaine over  time were more effective than a
single dose  in   interrupting or attenuating  the self-administration of
morphine and cocaine, supporting Lotsof's findings in human subjects
Popik et al. (1994) determined  Ibogaine to be a competitive inhibitor of
MK-801 binding to the NMDA receptor complex. Popik's findings were
supported by Mash et al. (1995).  MK-801 has been shown to attenuate
tolerance to opiates (Trujillo & Akil 1991) and alcohol (Khanna et al.
1993). MK-801 has also shown a blockade of "reverse tolerance" of
stimulants (Karler et al. 1989).  Ibogaine's effects on dopamine, a
substance hypothesized to be responsible for  reinforcing pleasurable
effects of drugs of abuse, and the dopamine system were found by
Maisonneuve et al. (1991), Broderick et al. (1992) and Sershen et al.
(1992).  Ibogaine binding to the kappa opiate receptor was reported by
Deecher et al. (1992). Both Ibogaine and its principal metabolite,
desmethyl ibogaine were shown to target serotonin transporters and to
elevate serotonin levels by Mash et al. (1995). The possibility of an
endogenous substance that may mimic Ibogaine was suggested to be norharman
by Cappendijk et al. (1994). Thus we begin to see a broad spectrum of
mechanisms by which Ibogaine may moderate use of substances so diverse as
opiate narcotics, stimulants and alcohol.
Studies not previously discussed have been accomplished concerning both
Ibogaine and its principal metabolite desmethyl ibogaine
(12-hydroxyibogamine or noribogaine) as well as, studies that have
demonstrated the complexity of addiction via the interaction of various
neurohormonal systems that are effected by Ibogaine or desmethyl ibogaine.
Schechter and Gordon (1993) determined that Ibogaine from the three
principal sources of the drug; Sigma Chemical, The National Institute on
Drug Abuse and NDA International, Inc. (ENDABUSE, NIH 10567) would allow
pre-clinical work using any research samples from the above suppliers to
be comparable.  Sershen et al (1994) reviewed the effects of Ibogaine on
serotonergic and dopaminergic interactions in the striatum of mice and
rats and then (1995) published on Ibogaine actions on  kappa opioid and
5-HT induced changes on dopamine release.  Pearl et al. (1995), continuing
research of the Albany Medical College Ibogaine working group published on
the effects of prior morphine exposure to enhance Ibogaine's effects in
reducing morphine-induced locomotor stimulation.  Rezvani et al.
demonstrated that Ibogaine would reduce alcohol intake in
alcohol-preferring rats (1995) adding to previous pre-clinical
demonstrations that Ibogaine would reduce the self-administration of
opiates and cocaine thus supporting Lotsof's  clinical findings that
Ibogaine was effective for attenuating opiate, stimulant and alcohol
self-administration.  Hough et al. added significant understanding to the
actions of Ibogaine in the publication of data on tissue distribution of
Ibogaine from intraperitoneal and subcutaneous injections.  The paper
concluded that the persistence of the Ibogaine in fat may contribute to
Ibogaine's long duration of action and that Ibogaine is subject to
substantial "first pass" effect  after IP dosing, but not after SC dosing.
 Responding to the concern of neurotoxicity in rats found by O'Hearn et
al. (1993), Molinan et al. (1994) published that Ibogaine at therapeutic
doses in the rat did not produce neurtoxicity, supporting Mash's (1995)
data that Ibogaine did not demonstrate neurotoxicity from multiple
administrations at therapeutic doses in monkeys or humans.
Concerning desmethyl ibogaine (noribogaine), Pearl et al. (1995) provided
an important insight into the mechanisms of actions of that drug in a
radioligand-binding study that showed desmethyl ibogaine to bind to all
opiate receptors.  Rezvani et al. (1995)  published data showing
noribogaine, like Ibogaine, to also reduce alcohol intake in rats.
Inherent in a review of the papers herein discussed and in discussions
with the researchers, a significant understanding of the actions and
interrelated actions of ibogaine and noribogaine are provided.
Ibogaine information source:  http://www.desk.nl/~ibogaine/

1. Aceto MD, Biological Evaluation of Compounds for Their Physical
Dependence Potential and Abuse Liability, NIDA Research Monograph 119:506,
   520-523, 1991.
2. Bastiaans J, The Psychiatric and Psychosomatic dimensions of Trauma,
personal   communication, 1991.
3. Broderick PS, Phelan FT & Berger SP, Ibogaine Alters Cocaine-Induced
Biogenic   and Psychostimulant Dysfunction, but Not [3H] GBR-12935 Binding
to the Dopamine Transporter Protein, Problems of Drug Dependence 1991:
Proceeding of the 53rd Annual Scientific Meeting, CPDD, NIDA Research
Monograph 119:285, 1992.
4. Broderick PS, Phelan FT, Eng F & Wechsler T, Ibogaine Modulates Cocaine
   Responses Which are Altered Due to Environmental Habituation:  In Vivo
   Microvoltammetric and Behavioral Studies, Pharmacology Biochemistry and
   Behavior, 49(3):711-728, 1994.
5. Cappendijk SLT & Dzoljic MR, Inhibitory Effects of Ibogaine on Cocaine
Self-   Administration in Rats, European Journal of Pharmacology,
241:261-265, 1993.
6. Cappendijk, SLT, Fekkes D, Dzoljic MR, The Inhibitory Effects of
Norharman on   morphine Withdrawal Syndrome in Rats:  Comparison with
Ibogaine, Behavioral    Brain Research, 65:117-119, 1994.
7. Deecher, DC, Teitler M, Soderlund DM, Bornmann WG, Kuehne ME & Glick
SD,   Mechanisms of Action of Ibogaine and Harmaline Congeners Based on
Radioligand   Binding Studies, Brain Research., 571:242-247, 1992.
8. Depoortere H, Neocortical Rhythmic Slow Activity During Wakefulness and
Sleep in Rats, Neuropsychobiology, 18:160-168, 1987.
9. Dzoljic ED, Kaplan CD & Dzoljic MR, Effects of Ibogaine on Naloxone
Precipitated Withdrawal Syndrome in Chronic Morphine Dependent Rats,
Archive of International Pharmacodynamics, 294:64-70, 1988.
10. Fernandez JW, Bwiti:  An Ethnography of Religious Imagination in
Africa,    Princeton University Press, 1982.
11. Glick SD, Rossman K, Rao NC, Maisonneuve IM and Carlson JN, Effects of
   Ibogaine on Acute Signs of Morphine Withdrawal in Rats:  Independence
From    Tremor, Neuropharmacology, 31(5):497-500, 1992
12. Glick SD, Rossman K, Steindorf S, Maisonneuve IM and Carlson JN,
Effects and Aftereffects of Ibogaine on Morphine Self-Administration in
Rats, European Journal of Pharmacology, 195:341-345. 1992.
13. Gollnhofer O & Sillans R, L'Iboga Psychotrope Africain (Iboga,  An
African    Psychotropic Agent), Psychotropes, 1(1):11-27, 1983.
14. Gollnhofer O & Sillans R, Usages Rituels de l'iboga au Gabon (Ritual
Uses    of Iboga in Gabon), Psychotropes, 2(3):95-108, 1985.
15. Goutarel R, Gollnhofer O & Sillans R, Pharmacodynamics And Therapeutic
   Applications of Iboga and Ibogaine, Psychedelic Monographs & Essays,
6:71-111,   1993.
16. Hough LB, Pearl SM and Glick SD, Tissue Distribution of Ibogaine After
Intraperitoneal and Subcutaneous Administration, Life Sciences, 58(7):PL
119-122, 1996.
17. Judd B, Ibogaine, Psychotherapy, and the Treatment of
Substance-related Disorders,   Eighth International Conference on Drug
Related Harm, NY, 1994.
18. Kaplan CD, Ketzer E, de Jong J, de Vries M, Reaching a State of
Wellness:     Multistage Explorations in Social Neuroscience, Social
Neuroscience Bulletin 6(1),   winter, 1993.
19. Karler R, Calder LD, Chaudhry IA, Turkanis SA, Blockade of "Reverse
Tolerance" to   Cocaine and Amphetamine by MK-801, Life Sciences
45:599-606, 1989.
20.Khanna JM, Kalant H, Shah G, Chau A, Effect of D-cycloserine on Rapid
Tolerance to  Ethanol, Pharmacology Biochemistry & Behavior 45(4):983-986,
21. Lotsof HS, U.S. patent  4,499,096; Rapid Method for Interrupting the
Narcotic   Addiction Syndrome, 1985.
22. Lotsof HS,  U.S. patent 4,587,243; Rapid Method for Interrupting the
Cocaine and   Amphetamine Abuse Syndrome, 1986.
23. Lotsof HS, U.S. patent 4,857,523; Rapid Method for Attenuating The
Alcohol    Dependency Syndrome, 1989.
24. Lotsof HS, U.S. Patent 5,026,697, Rapid Method for Interrupting or
Attenuating The   Nicotine/Tobacco Dependency Syndrome., 1991.
25. Lotsof HS, U.S. patent  5,124,994; Rapid Method for Interrupting or
Attenuating Poly- drug Dependency Syndromes, 1992.
26. Lotsof HS, Ibogaine in the Treatment of Chemical Dependence Disorders:
 Clinical   Perspectives, Bull. MAPS, 5(3):16-27, 1995.
27. Maisonneuve IM, Keller RW Jr. and Glick SD, Interactions Between
Ibogaine, A Potential Anti-Addictive Agent and Morphine:  An In Vivo
Microdialysis Study, European Journal of Pharmacology, 199:35-42, 1991.
28. Mash DC, Staley JK, Baumann, MH, Rothman RB and Hearn WL,
Identification of a   Primary Metabolite of Ibogaine that Targets
Serotonin Transporters and Elevates    Serotonin, Life Science,
57(3):45-50, 1995.
29. Mash DC, Staley JK, Pablo JP, Holohean AM, Hackman JC and Davidoff RA,
Properties  of Ibogaine and its Principal Metabolite (12-hydroxyibogamine)
at the MK-801    Binding Site of the NMDA Receptor Complex, Neuroscience
Letters, 192:53-56,    1995.
30. Molinari HH, Maisonneuve IM and Glick SD, Dose Dependence of Ibogaine
  Neurotoxicity, Society for Neuroscience Abstracts, 20. 505.4, 1994.
31. Naranjo C, Psychotherapeutic Possibilities of New  Fantasy Enhancing
Drugs, Clinical  Toxicology, 2(2):209. 1969.
32. Naranjo C, The Healing Journey, 174-228, Pantheon Books, Div. Random
House, NY,  1973.
33. O'Hearn E, Long DB and Molliver ME, Ibogaine Induces Glial Activation
in Parasagittal  Zones of the Cerebellum, Neuropharmacology and
Neurotoxicology,     NeuroReport,  4:299-302, 1993.
34. Pearl SM, Johnson DW, Glick SD, Prior Morphine Exposure Enhances
Ibogaine   Antagonism of Morphine-induced Locomotor Stimulation,
Psychopharmacology,    121:470-475, 1995.
35. Pearl SM. Herrick-Davis K, Teitler M, Glick SD, Radioligand-binding
Study of   Noribogaine, A Likely Metabolite of Ibogaine, Brain Research,
675:342-344,    1995.
36. Popik P, Layer RT & Skolnick P, The Putative anti-addictive Drug
Ibogaine is a   Competitive inhibitor of [3H]MK-801 Binding to the NMDA
Receptor Complex,    Psychopharmacology, 114:672-674, 1994.
37. Popik P, Layer RT and Skolnick P, 100 Years of Ibogaine:
Neurochemical and   Pharmacological Actions of a Putative Anti-addictive
Drug, Pharmacological    Reviews, 47(2):235-252, 1995
38. Rezvani AH, Overstreet DH and Lee Y-W, Attenuation of Alcohol Intake
by Ibogaine in  Three Strains of Alcohol-preferring Rats, Pharmacology
Biochemistry and     Behavior, 52(3):615-620, 1995.
39. Rezvani AH, Mash DC, Hearn WL, Lee YW and Overstreet DH; Noribogaine,
A Primary  Ibogaine Metabolite Reduces Alcohol Intake in P and Fawn-Hooded
Rats,     Alcoholism:  Clinical and Experimental Research, 19:15A (1995)
40. Sanchez-Ramos J  & Mash DC, Ibogaine Research Update:  Phase I Human
Study,   MAPS, IV(4):11 Spring 1994.
41. Schechter MD and Gordon L, Comparison of the Behavioral Effects of
Ibogaine from   Three Sources:  Mediation of Discriminative Activity,
European Journal of     Pharmacology, 249:79-84, 1993
42. Sershen H, Hashim A, Harsing L, & Lajtha A, Ibogaine Antagonizes
Cocaine-   Induced Locomotor Activity in Mice, Life Sciences,
50:1079-1086, 1992.
43. Sershen H, Hashim A, & Lajtha A, Ibogaine Reduces Preferences for
Cocaine    Consumption in C57BL/6By Mice, Pharmacology, Biochemistry and
Behavior, 47   (1):13- 19, 1994.
44. Sershen H, Hashim A and Lajtha A, Effect of Ibogaine on Serotonergic
and    Dopaminergic Interactions in Striatum from Mice and Rats,
Neuroscience Research,   19(11):1463-1466, 1994.
45. Sershen H, Hashim A and Lajtha A, The Effect on k-Opioid and
5-HT(3)Induced   Changes in Stimulation-evoked Dopamine Release In Vitro
46. Sheppard SG, A Preliminary Investigation of Ibogaine: Case Reports and
   Recommendations for Further Study, J. Substance Abuse Treatment,
11(4):379-385, 1994.
47. Sisko B, Interrupting Drug Dependency with Ibogaine:  A Summery of
Four Case   Histories, MAPS, IV(2):15-23, Summer  1993.
48. Trujillo KA & Akil H, Inhibition of Morphine Tolerance and Dependence
by NMDA   Receptor Antagonist MK-801, Science, 2512:85-87, 1991.
49. Woods HW, Medzihardsky F, Smith CB, Winger GD and Prince CP, 1989
Annual Report, Evaluation of New Compounds for Opioid Activity, NIDA
Research Monograph 95:563, 655-656, 1990.
50. Zeff L, First International Ibogaine Conference, Paris, January 1987
(video tape).